NCT07506369 Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans
| NCT ID | NCT07506369 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Gentofte, Copenhagen |
| Condition | Obesity & Overweight |
| Study Type | INTERVENTIONAL |
| Enrollment | 18 participants |
| Start Date | 2026-04 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 18 participants in total. It began in 2026-04 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The two pancreatic hormones amylin and pancreatic polypeptide (PP) has been linked to satiety and energy metabolism. The goal of this this study is to determine the separate and combined effects of the two hormones on food intake and other exploratory endpoints related to metabolism in healthy humans. The aim of this study is to investigate the interaction between the hormones and obtain insight into the physiology of the hormones. The healthy participants will undergo 4 study days in a randomised order receiving the following infusions for 5 hours: A) Amylin + PP B) Amylin + Placebo C) Placebo + PP D) Placebo + Placebo Throughout the day blood samples will be collected and gallbladder motility will be evaluated. Further, indirect calorimetry and heart rate/blood pressure measurement will be performed.
Eligibility Criteria
Inclusion Criteria: * Male * Age between 18 and 65 years at the time of inclusion * Body mass index 18-27 kg/m2 * Fat percentage \< 20% * Informed oral and written consent Exclusion Criteria: * Anaemia (haemoglobin below normal range) * History of hepatobiliary and/or gastrointestinal disorder(s) * Kidney disease * Previous gastric or intestinal resection, cholecystectomy and/or any major intra- abdominal surgery (including bariatric surgery) * Previous pancreatic disease and/or neoplasia * Regular tobacco smoking and/or use of other nicotine products * Glycated haemoglobin (HbA1c) ≥48 and/or type 1 diabetes or type 2 diabetes requiring medical treatment * Initiation of special diets, lifestyle changes and/or weight loss \>5% of total body weight within three months prior to or during study period * Any physical or psychological condition or ongoing medication the investigator group suspects would interfere with trial participation
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07506369 clinical trial?
This trial is open to male participants only, aged 18 Years or older, up to 65 Years, studying Obesity & Overweight. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07506369 currently recruiting?
Yes, NCT07506369 is actively recruiting participants. Contact the research team at andreas.holst.lange@rehionh.dk for enrollment information.
Where is the NCT07506369 trial being conducted?
This trial is being conducted at Hellerup, Denmark.
Who is sponsoring the NCT07506369 clinical trial?
NCT07506369 is sponsored by University Hospital, Gentofte, Copenhagen. The trial plans to enroll 18 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.